[New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki
Masataka
M
Department of Internal Medicine, Research Institute and Practice for Involutional Disease.
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D016723:Bone Remodeling / Q000187:drug effects; D001842:Bone and Bones / Q000378:metabolism; D002986:Clinical Trials as Topic; D015195:Drug Design; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D009942:Organometallic Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D044169:Receptors, Calcium-Sensing / Q000502:physiology; D013876:Thiophenes / Q000494:pharmacology / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D009942:Organometallic Compounds; D044169:Receptors, Calcium-Sensing; D013876:Thiophenes; C081587:strontium ranelate